FI972708L - Immunoterapeuttisia imideja/amideja ja niiden käyttö TNFalfa:n tasojen alentamiseksi - Google Patents

Immunoterapeuttisia imideja/amideja ja niiden käyttö TNFalfa:n tasojen alentamiseksi Download PDF

Info

Publication number
FI972708L
FI972708L FI972708A FI972708A FI972708L FI 972708 L FI972708 L FI 972708L FI 972708 A FI972708 A FI 972708A FI 972708 A FI972708 A FI 972708A FI 972708 L FI972708 L FI 972708L
Authority
FI
Finland
Prior art keywords
amides
immunotherapeutic
imides
tnfalpha levels
tnfalpha
Prior art date
Application number
FI972708A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI972708A7 (fi
FI972708A0 (fi
Inventor
Mary Shire
David I Stirling
Original Assignee
Celgene Corp
Muller George
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Muller George filed Critical Celgene Corp
Publication of FI972708A0 publication Critical patent/FI972708A0/fi
Publication of FI972708A7 publication Critical patent/FI972708A7/fi
Publication of FI972708L publication Critical patent/FI972708L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI972708A 1994-12-30 1995-11-20 Immunoterapeuttisia imideja/amideja ja niiden käyttö TNFalfa:n tasojen alentamiseksi FI972708L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36666794A 1994-12-30 1994-12-30
PCT/US1995/015119 WO1996020705A1 (fr) 1994-12-30 1995-11-20 IMIDES/AMIDES IMMUNOTHERAPEUTIQUES ET LEUR UTILISATION POUR REDUIRE LE NIVEAU DU FACTEUR α DE NECROSE DE TUMEURS

Publications (3)

Publication Number Publication Date
FI972708A0 FI972708A0 (fi) 1997-06-23
FI972708A7 FI972708A7 (fi) 1997-08-29
FI972708L true FI972708L (fi) 1997-08-29

Family

ID=23443993

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972708A FI972708L (fi) 1994-12-30 1995-11-20 Immunoterapeuttisia imideja/amideja ja niiden käyttö TNFalfa:n tasojen alentamiseksi

Country Status (18)

Country Link
EP (1) EP0797437B1 (fr)
JP (1) JPH10511678A (fr)
AT (1) ATE200621T1 (fr)
AU (1) AU696817B2 (fr)
CA (1) CA2208672C (fr)
CZ (1) CZ290372B6 (fr)
DE (1) DE69520750T2 (fr)
DK (1) DK0797437T3 (fr)
ES (1) ES2155537T3 (fr)
FI (1) FI972708L (fr)
GR (1) GR3036131T3 (fr)
HU (1) HU226558B1 (fr)
NZ (1) NZ296925A (fr)
PL (1) PL185101B1 (fr)
PT (1) PT797437E (fr)
RU (1) RU2164514C2 (fr)
SK (1) SK86997A3 (fr)
WO (1) WO1996020705A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658940A (en) * 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
DE69700616T2 (de) * 1996-07-02 2000-03-16 Nisshin Flour Milling Co., Ltd. Imid derivate
ES2262184T3 (es) * 1996-08-05 2006-11-16 Myriad Genetics, Inc. Utilizacion de mimeticos de hojas beta como inhibidores de proteasa y de kinasa o como inhibidores de factores de transcripcion.
EP1661566A3 (fr) * 1996-08-05 2008-04-16 Myriad Genetics, Inc. Utilisation de mimétiques de feuillets beta comme inhibiteurs de protéase et de kinase ou comme inhibiteurs de facteurs de transcription
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
CA2438641A1 (fr) 2001-02-15 2002-08-22 King Pharmaceuticals, Inc. Compositions pharmaceutiques stabilisees, compositions d'hormone de thyroide et technique de preparation
CA2439410C (fr) 2001-02-27 2011-09-06 William D. Figg Analogues de thalidomide utilises comme inhibiteurs potentiels de l'angiogenese
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
EP1663223B1 (fr) 2003-09-17 2014-01-01 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Analogues du thalidomide comme inhibiteurs de tnf-alpha
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4467097A (en) * 1982-09-29 1984-08-21 General Electric Company Method for making aromatic bis(etherimide)s
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines

Also Published As

Publication number Publication date
FI972708A7 (fi) 1997-08-29
PL185101B1 (pl) 2003-02-28
HUT77978A (hu) 1999-01-28
CZ203597A3 (en) 1997-11-12
DK0797437T3 (da) 2001-06-05
ES2155537T3 (es) 2001-05-16
GR3036131T3 (en) 2001-09-28
EP0797437A1 (fr) 1997-10-01
CZ290372B6 (cs) 2002-07-17
CA2208672C (fr) 2008-02-12
AU696817B2 (en) 1998-09-17
DE69520750D1 (de) 2001-05-23
RU2164514C2 (ru) 2001-03-27
HU226558B1 (en) 2009-03-30
FI972708A0 (fi) 1997-06-23
NZ296925A (en) 1998-06-26
AU4166796A (en) 1996-07-24
PT797437E (pt) 2001-07-31
SK86997A3 (en) 1998-01-14
ATE200621T1 (de) 2001-05-15
CA2208672A1 (fr) 1996-07-11
WO1996020705A1 (fr) 1996-07-11
EP0797437B1 (fr) 2001-04-18
DE69520750T2 (de) 2001-09-13
JPH10511678A (ja) 1998-11-10
PL321071A1 (en) 1997-11-24

Similar Documents

Publication Publication Date Title
FI990180A7 (fi) Uusia immunoterapeuttisia aineita ja niiden käyttö sytokiini-tasojen pienentämiseksi
IS4481A (is) Díhýdrópyramídín og notkun þeirra
DE69412130D1 (de) Kühlcontainer und endrahmen
FI951801L (fi) CTLA4-molekyylit ja IL4:sitovat molekyylit sekä näiden käyttö
KR960012626A (ko) 클립 및 그 제작 방법
NO2008002I1 (no) Protiokonazol og salter derav
DK0804078T3 (da) Sammensætning og anvendelse deraf
BR9506832A (pt) N-pirazolilanilinas e n-pirazolilaminopiridinas
BR9502407A (pt) Composição lubrificante e concetrado
FI972245A0 (fi) Meso-monojodisubstituoidut tetramakrosykliset yhdisteet sekä niiden valmistus- ja käyttömenetelmät
FI972708L (fi) Immunoterapeuttisia imideja/amideja ja niiden käyttö TNFalfa:n tasojen alentamiseksi
PT755386E (pt) Derivado de benzamida composicoes contendo o referido derivado e sua utilizacao
DE59501869D1 (de) Leichtmörtel und seine Verwendung
FI965043L (fi) Suuriaffiniteettisia melatoniinireseptoreita ja niiden käyttö
DE69619763D1 (de) Positiv arbeitende Photolockzusammensetzung und Photosensibilisatoren
BR9510062A (pt) Macromonômeto esterificado e composição
NO964541L (no) Porphacyanin og CNC-utvidete porphyriner
DE69600829D1 (de) Mikrobizide Zusammensetzung und deren Verwendung
IT1273540B (it) Fosfiti-hals e fosforammidi-hals come stabilizzanti
DE69530446D1 (de) Ozonisator und seine Verwendung
DE69328467D1 (de) Polyamidzusammensetzung und Verwendung
FI964854L (fi) Hydroksitioasetamidien valmistus ja niiden käyttö bentsotiofeenien synteesissä
NO972216D0 (no) Acrotein-frigjörende sammensetning og dens anvendelse
DE69506459D1 (de) Zwirnverfahren und Zwirnvorrichtung
BR9507133A (pt) N-aril e n-alquilsulfonilaminais